How AstraZeneca's revivified pipeline could boost Pfizer
This article was originally published in Scrip
While the main motive for Pfizer's pursuit of AstraZeneca has been squarely placed at the tax man's door, if the acquisition does go through the US company will find itself in possession of a revivified, but still largely immature, drug pipeline.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.